241 related articles for article (PubMed ID: 23887673)
21. DACH1: its role as a classifier of long term good prognosis in luminal breast cancer.
Powe DG; Dhondalay GK; Lemetre C; Allen T; Habashy HO; Ellis IO; Rees R; Ball GR
PLoS One; 2014; 9(1):e84428. PubMed ID: 24392136
[TBL] [Abstract][Full Text] [Related]
22. NF-kappaB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or ErbB2 overexpression and MAPK hyperactivation.
Van Laere SJ; Van der Auwera I; Van den Eynden GG; van Dam P; Van Marck EA; Vermeulen PB; Dirix LY
Br J Cancer; 2007 Sep; 97(5):659-69. PubMed ID: 17700572
[TBL] [Abstract][Full Text] [Related]
23. Differential CARM1 expression in prostate and colorectal cancers.
Kim YR; Lee BK; Park RY; Nguyen NT; Bae JA; Kwon DD; Jung C
BMC Cancer; 2010 May; 10():197. PubMed ID: 20462455
[TBL] [Abstract][Full Text] [Related]
24. High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses.
Abd El-Rehim DM; Ball G; Pinder SE; Rakha E; Paish C; Robertson JF; Macmillan D; Blamey RW; Ellis IO
Int J Cancer; 2005 Sep; 116(3):340-50. PubMed ID: 15818618
[TBL] [Abstract][Full Text] [Related]
25. CORRELATION BETWEEN CLINICAL PATHOLOGY OF LUMINAL B BREAST CANCER AND DETERMINATION OF ESTROGEN RECEPTOR, PROGESTERONE RECEPTOR AND HER2 EXPRESSION COMBINED WITH NUCLEAR MORPHOLOGY.
Yin D; Wang YL; Wang YF; Yang L; Zhang L; Tang C; Xie W; Ma Y
J Biol Regul Homeost Agents; 2015; 29(3):579-87. PubMed ID: 26403396
[TBL] [Abstract][Full Text] [Related]
26. Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer.
Rennstam K; McMichael N; Berglund P; Honeth G; Hegardt C; Rydén L; Luts L; Bendahl PO; Hedenfalk I
Breast Cancer Res Treat; 2010 Jul; 122(2):315-24. PubMed ID: 19795205
[TBL] [Abstract][Full Text] [Related]
27. Association between Ultrasound Features and the 21-Gene Recurrence Score Assays in Patients with Oestrogen Receptor-Positive, HER2-Negative, Invasive Breast Cancer.
Chae EY; Moon WK; Kim HH; Kim WH; Cha JH; Shin HJ; Choi WJ; Han W; Noh DY; Lee SB; Ahn SH
PLoS One; 2016; 11(6):e0158461. PubMed ID: 27362843
[TBL] [Abstract][Full Text] [Related]
28. CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy.
Alfarsi LH; Ansari RE; Craze ML; Toss MS; Masisi B; Ellis IO; Rakha EA; Green AR
Breast Cancer Res Treat; 2019 Dec; 178(3):535-544. PubMed ID: 31471836
[TBL] [Abstract][Full Text] [Related]
29. Alpha- and beta-adrenergic receptor (AR) protein expression is associated with poor clinical outcome in breast cancer: an immunohistochemical study.
Powe DG; Voss MJ; Habashy HO; Zänker KS; Green AR; Ellis IO; Entschladen F
Breast Cancer Res Treat; 2011 Nov; 130(2):457-63. PubMed ID: 21298476
[TBL] [Abstract][Full Text] [Related]
30. Aging impacts transcriptomes but not genomes of hormone-dependent breast cancers.
Yau C; Fedele V; Roydasgupta R; Fridlyand J; Hubbard A; Gray JW; Chew K; Dairkee SH; Moore DH; Schittulli F; Tommasi S; Paradiso A; Albertson DG; Benz CC
Breast Cancer Res; 2007; 9(5):R59. PubMed ID: 17850661
[TBL] [Abstract][Full Text] [Related]
31. Expression of luminal and basal cytokeratins in human breast carcinoma.
Abd El-Rehim DM; Pinder SE; Paish CE; Bell J; Blamey RW; Robertson JF; Nicholson RI; Ellis IO
J Pathol; 2004 Jun; 203(2):661-71. PubMed ID: 15141381
[TBL] [Abstract][Full Text] [Related]
32. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
[TBL] [Abstract][Full Text] [Related]
33. PELP1 oncogenic functions involve CARM1 regulation.
Mann M; Cortez V; Vadlamudi R
Carcinogenesis; 2013 Jul; 34(7):1468-75. PubMed ID: 23486015
[TBL] [Abstract][Full Text] [Related]
34. Salivary duct carcinomas can be classified into luminal androgen receptor-positive, HER2 and basal-like phenotypes.
Di Palma S; Simpson RH; Marchiò C; Skálová A; Ungari M; Sandison A; Whitaker S; Parry S; Reis-Filho JS
Histopathology; 2012 Oct; 61(4):629-43. PubMed ID: 22882517
[TBL] [Abstract][Full Text] [Related]
35. Inference of the Basal epithelial phenotype in breast carcinoma from differential marker expression, using tissue microarrays in triple negative breast cancer and women younger than 35.
Nassar A; Sussman ZM; Lawson D; Cohen C
Breast J; 2012 Sep; 18(5):399-405. PubMed ID: 22882580
[TBL] [Abstract][Full Text] [Related]
36. Gene expression profiling of luminal B breast cancers reveals NHERF1 as a new marker of endocrine resistance.
Karn T; Ruckhäberle E; Hanker L; Müller V; Schmidt M; Solbach C; Gätje R; Gehrmann M; Holtrich U; Kaufmann M; Rody A
Breast Cancer Res Treat; 2011 Nov; 130(2):409-20. PubMed ID: 21203899
[TBL] [Abstract][Full Text] [Related]
37. MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours.
Green AR; Aleskandarany MA; Agarwal D; Elsheikh S; Nolan CC; Diez-Rodriguez M; Macmillan RD; Ball GR; Caldas C; Madhusudan S; Ellis IO; Rakha EA
Br J Cancer; 2016 Apr; 114(8):917-28. PubMed ID: 26954716
[TBL] [Abstract][Full Text] [Related]
38. Identification of a basal-like subtype of breast ductal carcinoma in situ.
Livasy CA; Perou CM; Karaca G; Cowan DW; Maia D; Jackson S; Tse CK; Nyante S; Millikan RC
Hum Pathol; 2007 Feb; 38(2):197-204. PubMed ID: 17234468
[TBL] [Abstract][Full Text] [Related]
39. ESPL1 is a candidate oncogene of luminal B breast cancers.
Finetti P; Guille A; Adelaide J; Birnbaum D; Chaffanet M; Bertucci F
Breast Cancer Res Treat; 2014 Aug; 147(1):51-9. PubMed ID: 25086634
[TBL] [Abstract][Full Text] [Related]
40. The prognostic significance of PELP1 expression in invasive breast cancer with emphasis on the ER-positive luminal-like subtype.
Habashy HO; Powe DG; Rakha EA; Ball G; Macmillan RD; Green AR; Ellis IO
Breast Cancer Res Treat; 2010 Apr; 120(3):603-12. PubMed ID: 19495959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
